Key statistics dashboard for Metagenomi, Inc. Common Stock (MGX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases.
Stock Data
| Price | $1.15 |
| Market Cap | $43M |
| Beta | 0.57 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.46 |
| Price / Book | 0.38 |
| P/S | 3.19 |
| P/FCF | -0.50 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 74.29% |
| EBIT Margin | -690.60% |
| EBITDA Margin | -652.52% |
| Operating Margin | -741.58% |
| Net Margin | -689.20% |
Financial Health
| Current Ratio | 4.50 |
| Quick Ratio | 4.50 |
| Cash Ratio | 1.41 |
| Debt / Equity | 0.34 |
| Debt / Assets | 21.72% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.36 |
| Book Value per share | 2.99 |
| Cash per share | 3.20 |
| FCF per share | -2.28 |
| Tangible Book Value per share | 2.99 |
| Dividend per share | 0.00 |
Related companies: ADVM · ALXO · ARTV · ATYR · CNTB · DTIL · IFRX
Explore sector: Healthcare · Biotechnology
More sections of MGX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks